Wednesday, 17 Oct 2018

You are here

Predicting Autoimmune Progression in ANA+ Patients

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.

This prospective observational study studied 118 individuals who were ANA positive, had one or more SLE criteria for <12 months and were treatment-naïve. They also used 49 healthy controls (HCs) and 114 SLE were used as negative and positive controls. 

Over a 12-month period, 19/118 (16%) progressed to AI-CTD (SLE=14, primary Sjogren’s=5).

Baseline IFN (IFN-A, IFN-B) scores differed among At-Risk, HCs and SLE groups (p<0.001) and were elevated in At-Risk who progressed to AI-CTD at 12 months.

Those who progressed to AI-CTD did not have other distinguishing baseline clinical characteristics or ultrasound findings.

The odds of progression were more likely in those with a family history of autoimmune rheumatic disease  (OR 8.2 (95% CI 1.58 to 42.53) and IFN-Score-B (OR 3.79;1.50–9.58).

While gene testing for IFN signatures would be interesting, if not advantageous, the question remains whether this would be cost effective and predictive in individuals without a positive family history and without lupus-specific clinical characteristics.  Nonethless, this approach allows for the potential of early stratification of individuals At-Risk for AI-CTD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.